IsoPlexis Corp
NASDAQ:ISO
Intrinsic Value
IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ISO.
IsoPlexis Corp's market capitalization is 30.2m USD.
ISO stock price is 0.7616 USD.
ISO.
ISO. Open DCF Valuation
ISO. Open Relative Valuation
ISO.
ISO's Revenue has dropped by 3% over the past 12 months.
ISO's D/E (Debt to Equity) is equal to 1.12.
ISO has positive Net Debt. This means that the company has more debt (46m USD) than cash and short-term investments (37m USD).
ISO's long-term assets (109m USD) exceed its long-term liabilties (68m USD).
ISO has negative Gross Profit for the last twelve months.
ISO has negative Operating Income for the last twelve months.
ISO has negative Net Income for the last twelve months.
ISO's ROE (Return on Equity) for the past 12 months is negative and is equal to -116%.
ISO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -155%.
ISO's Revenue is forecast to grow at a rate of 63% per year over the next 3 years.
ISO has negative Free Cash Flow for the last twelve months.
ISO has negative three-year average ROE (Return on Equity): -75%. The company is not efficient at transforming stockholders' equity into net income.
ISO has negative three-year average ROIC (Return on Invested Capital): -211%. The company is not efficient at using invested capital to generate operating income.
ISO's short-term assets (72m USD) exceed its short-term liabilties (18m USD).
ISO's Altman Z-Score is very low and is equal to -5.13.
ISO doesn't generate enough operating income (-97m USD) to safely cover interest payments on its debt (5m USD).
Fundamental Analysis
IsoPlexis Corp
Balance Sheet Decomposition
IsoPlexis Corp
| Current Assets | 71.9m |
| Cash & Short-Term Investments | 37.5m |
| Receivables | 4.5m |
| Other Current Assets | 29.9m |
| Non-Current Assets | 37.2m |
| PP&E | 16.3m |
| Intangibles | 19.8m |
| Other Non-Current Assets | 1.1m |
| Current Liabilities | 17.7m |
| Accounts Payable | 2.8m |
| Accrued Liabilities | 12.9m |
| Other Current Liabilities | 2m |
| Non-Current Liabilities | 50.1m |
| Long-Term Debt | 46.4m |
| Other Non-Current Liabilities | 3.7m |
Earnings Waterfall
IsoPlexis Corp
|
Revenue
|
16.8m
USD
|
|
Cost of Revenue
|
-17.7m
USD
|
|
Gross Profit
|
-926k
USD
|
|
Operating Expenses
|
-96.1m
USD
|
|
Operating Income
|
-97m
USD
|
|
Other Expenses
|
-9m
USD
|
|
Net Income
|
-106m
USD
|
Free Cash Flow Analysis
IsoPlexis Corp
What is Free Cash Flow?
ISO Profitability Score
Profitability Due Diligence
IsoPlexis Corp's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
IsoPlexis Corp's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ISO Solvency Score
Solvency Due Diligence
IsoPlexis Corp's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
IsoPlexis Corp's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ISO Price Targets Summary
IsoPlexis Corp
Ownership
ISO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ISO Price
IsoPlexis Corp
| Average Annual Return | -12.59% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -96% |
| Market Capitalization | 30.2m USD |
| Shares Outstanding | 39 763 100 |
| Percentage of Shares Shorted | 0.59% |
Company Profile
IsoPlexis Corp
Country
Industry
Market Cap
Dividend Yield
Description
IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. The company is headquartered in Branford, Connecticut and currently employs 459 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in building solutions to develop curative medicines and personalized therapeutics. The firm's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The firm's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. IsoSpeak software provides automated data analysis and accelerated insights. Its subsidiary includes IsoPlexis UK Limited.
You don't have any saved screeners yet
